Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Hepatocellular 3Breast Neoplasms 3Sarcoma 2Wilms Tumor 1Urinary Bladder Neoplasms 1Upper Tract Urothelial Carcinoma 1Triple Negative Breast Neoplasms 1Subcutaneous panniculitis-like T-cell lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Osteosarcoma 1Immunoblastic Lymphadenopathy 1Enteropathy-Associated T-Cell Lymphoma 1Breast Cancer Organoids 1

Interventions

Methotrexate 21Ifosfamide 21Cyclophosphamide 19Doxorubicin 17Cisplatin 14Filgrastim 13Gemcitabine 12Etoposide 11Leucovorin 9apatinib 8fludarabine 7glucarpidase 6Vincristine 6Temozolomide 6Radiotherapy 6Nivolumab 6Neoadjuvant Therapy 6Drug Therapy 6Carboplatin 6regorafenib 5cabozantinib 5Zoledronic Acid 5Topotecan 5Mesna 5Irinotecan 5Granulocyte Colony-Stimulating Factor 5Docetaxel 5pembrolizumab 4pegfilgrastim 4camrelizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Osteosarcoma × pirarubicin × Clear all
NCT06714383 2024-12-03

Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma

Peking University People's Hospital

Phase 2 Recruiting
50 enrolled
Sarcoma

Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡